New drug combo shows promise against advanced kidney cancer
NCT ID NCT03172754
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 25 times
Summary
This study tests a combination of two drugs, nivolumab and axitinib, in people with advanced kidney cancer. The first part finds the safest dose, and the second part checks how well the drugs shrink tumors. About 98 participants, both previously treated and untreated, are enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cornell
New York, New York, 10021, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Johns Hopkins
Baltimore, Maryland, 21231, United States
-
US Oncology and Hematology
Albany, New York, 12206, United States
Conditions
Explore the condition pages connected to this study.